In This Section      
 

Search Results

Title:
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Flat Epithelial Atypia (FEA) or Intraductal Papilloma without Atypia (IPWA) by Core Needle Biopsy (TBCRC 034)
Protocol Number:
TBCRC034
Phase:
NULL
Physician:
Lisa Jacobs
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Sibley Memorial Hospital
Purpose:
The purpose of this study is to find out how often cancer is identified by breast excisional biopsy (removal of tissue for the purpose of diagnosis) or surgery near the location of an initial breast core biopsy that showed abnormalities that were not cancer, such as flat epithelial atypia (FEA) or intraductal papilloma without atypia (IPWA).
Eligibility:
Women who have been diagnosed with flat epithelial atypia (FEA) or intraductal papilloma without atypia (IPWA) by breast core needle biopsy may join.
Treatment:
During your standard of care visit with a doctor, you will have a physical exam and you will be asked questions about your general health, medical history and family history. Within 6 months of your core needle biopsy you will have a standard of care surgical procedure (most often a breast excisional biopsy or a lumpectomy) as decided between you or your doctor. This is a procedure during which the area of breast tissue found to have FEA or IPWA is removed by a surgeon. After your surgery, we will send the information that the pathologists used to review your original core needle biopsy that showed FEA or IPWA as well as information from your surgery to the doctors leading this study. After your surgery, your doctor will review with you the pathology results from your tissue removed during surgery. Based on the results, your doctor may recommend additional procedures or treatment. Any additional treatment is not directed by this study.
Population:
Adult
Last Update
03/05/2019 05:03 AM